|
1
|
Ayala M and Chen E: The influence of
topical prostaglandin analogues in inflammation after selective
laser trabeculoplasty treatment. J Ocul Pharmacol Ther. 28:118–122.
2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zhang XL and Qin L: Efficacy of travoprost
for the treatment of patients with glaucoma. Medicine (Baltimore).
98(e16526)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Stalmans I, Oddone F, Cordeiro MF, Hommer
A, Montesano G, Ribeiro L, Sunaric-Mégevand G and Rossetti L:
Comparison of preservative-free latanoprost and preservative-free
bimatoprost in a multicenter, randomized, investigator-masked
cross-over clinical trial, the SPORT trial. Graefes Arch Clin Exp
Ophthalmol. 254:1151–1158. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Congdon N, O'Colmain B, Klaver CC, Klein
R, Muñoz B, Friedman DS, Kempen J, Taylor HR and Mitchell P: Eye
Diseases Prevalence Research Group. Causes and prevalence of visual
impairment among adults in the United States. Arch Ophthalmol.
122:477–485. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Song P, Wang J, Bucan K, Theodoratou E,
Rudan I and Chan KY: National and subnational prevalence and burden
of glaucoma in China: A systematic analysis. J Glob Health.
7(020705)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ernest PJ, Schouten JS, Beckers HJ,
Hendrikse F, Prins MH and Webers CA: An evidence-based review of
prognostic factors for glaucomatous visual field progression.
Ophthalmology. 120:512–519. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Denis P, Launois R, Devaux M and Berdeaux
G: Comparison of diurnal intraocular pressure control by
latanoprost versus travoprost: Results of an observational survey.
Clin Drug Investig. 26:703–714. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Garway-Heath DF, Crabb DP, Bunce C,
Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR,
Broadway DC, Cunliffe IA, et al: Latanoprost for open-angle
glaucoma (UKGTS): A randomised, multicentre, placebo-controlled
trial. Lancet. 385:1295–1304. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Peace JH, Ahlberg P, Wagner M, Lim JM,
Wirta D and Branch JD: Polyquaternium-1-preserved travoprost 0.003%
or benzalkonium chloride-preserved travoprost 0.004% for glaucoma
and ocular hypertension. Am J Ophthalmol. 160:266–274.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chander A, Kapoor H and Thomas S:
Comparison of the efficacy and safety of bimatoprost (0.03%) and
travoprost (0.004%) in patients with primary open angle glaucoma.
Nepal J Ophthalmol. 5:75–80. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tang W, Zhang F, Liu K and Duan X:
Efficacy and safety of prostaglandin analogues in primary
open-angle glaucoma or ocular hypertension patients: A
meta-analysis. Medicine (Baltimore). 90(e16597)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shoji T, Sato H, Mizukawa A, Hirota N,
Enoki T, Kojima T, Kanda T and Takeuchi M: Hypotensive effect of
latanoprost/timolol versus travoprost/timolol fixed combinations in
NTG patients: A randomized, multicenter, crossover clinical trial.
Invest Ophthalmol Vis Sci. 54:6242–6247. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rahmatnejad K, Rapuano CJ, Ichhpujani P,
Wizov SS, Moster MR, Hark LA and Katz LJ: The effects of
latanoprost with benzalkonium chloride versus travoprost with
SofZia on the ocular surface. Eye Contact Lens. 44 (Suppl
2):S93–S98. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
El Hajj Moussa WG, Farhat RG, Nehme JC,
Sahyoun MA, Schakal AR, Jalkh AE, Abi Karam MP and Azar GG:
Comparison of efficacy and ocular surface disease index score
between bimatoprost, latanoprost, travoprost, and tafluprost in
glaucoma patients. J Ophthalmol. 2018(1319628)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Alcon Laboratories Inc.: Package leaflet:
Information for the user TRAVATAN® 40 micrograms/ml eye
drops, solution travoprost. Available from: https://www.medicines.org.uk/emc/files/pil.1556.pdf.
Accessed October 1, 2019.
|
|
16
|
Pfizer Inc.. Package leaflet: Information
for the user Xalatan® 50 micrograms/ml eye drops,
solution latanoprost. Available from: https://www.medicines.org.uk/emc/files/pil.1616.pdf.
Accessed October 1, 2019.
|
|
17
|
Konstas AG, Kozobolis VP, Katsimpris IE,
Boboridis K, Koukoula S, Jenkins JN and Stewart WC: Efficacy and
safety of latanoprost versus travoprost in exfoliative glaucoma
patients. Ophthalmology. 114:653–657. 2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Parmaksiz S, Yüksel N, Karabas VL, Ozkan
B, Demirci G and Caglar Y: A comparison of travoprost, latanoprost,
and the fixed combination of dorzolamide and timolol in patients
with pseudoexfoliation glaucoma. Eur J Ophthalmol. 16:73–80.
2006.PubMed/NCBI
|
|
19
|
Blondeau P, Hamid M and Ghalie Z:
Prospective randomized clinical trial on the effects of
latanoprost, travoprost and bimatoprost on latanoprost
non-responders. J Fr Ophtalmol. 42:894–899. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sawada A, Yamamoto T and Takatsuka N:
Randomized crossover study of latanoprost and travoprost in eyes
with open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol.
250:123–129. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mishra D, Sinha BP and Kumar MS: Comparing
the efficacy of latanoprost (0.005%), bimatoprost (0.03%),
travoprost (0.004%), and timolol (0.5%) in the treatment of primary
open angle glaucoma. Korean J Ophthalmol. 28:399–407.
2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Setia MS: Methodology series module 3:
Cross-sectional studies. Indian J Dermatol. 61:261–264.
2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yan DB, Battista RA, Haidich AB and
Konstas AG: Comparison of morning versus evening dosing and 24-h
post-dose efficacy of travoprost compared with latanoprost in
patients with open-angle glaucoma. Curr Med Res Opin. 24:3023–3027.
2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fain JM, Kotak S, Mardekian J, Bacharach
J, Edward DP, Rauchman S, Brevetti T, Fox JL and Lovelace C: A
multicenter, retrospective chart review study comparing index
therapy change rates in open-angle glaucoma or ocular hypertension
patients newly treated with latanoprost or travoprost-Z
monotherapy. BMC Ophthalmol. 11(13)2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Rödter TH, Knippschild S, Baulig C and
Krummenauer F: Meta-analysis of the concordance of
Icare® PRO-based rebound and Goldmann applanation
tonometry in glaucoma patients. Eur J Ophthalmol. 30:245–252.
2020.PubMed/NCBI View Article : Google Scholar
|
